Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51).

[1]  H. Nagai,et al.  Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. , 2007, Toxicology and applied pharmacology.

[2]  S. Ekins,et al.  Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors , 2007, Drug Metabolism and Disposition.

[3]  S. Grdadolnik,et al.  Synthesis, conformation, and stereodynamics of a salt of 2-{[2-(3,4-dichlorophenyl)- ethyl]propylamino}-1-pyridin-3-ylethanol. , 2006, The Journal of organic chemistry.

[4]  M. Waterman,et al.  Sterol 14α-demethylase, an abundant and essential mixed-function oxidase , 2005 .

[5]  Jure Acimovic,et al.  Cholesterogenic lanosterol 14alpha-demethylase (CYP51) is an immediate early response gene. , 2005, Endocrinology.

[6]  M. Davidson.  Reducing residual risk for patients on statin therapy: the potential role of combination therapy. , 2005, The American journal of cardiology.

[7]  E. Lalli,et al.  Combinations of genetic changes in the human cAMP-responsive element modulator gene: a clue towards understanding some forms of male infertility? , 2005, Molecular human reproduction.

[8]  D. Gómez-Coronado,et al.  Sterol stringency of proliferation and cell cycle progression in human cells. , 2005, Biochimica et biophysica acta.

[9]  S. Baker.  Molecular clues into the pathogenesis of statin‐mediated muscle toxicity , 2005, Muscle & nerve.

[10]  D. Gómez-Coronado,et al.  Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.M400407-JLR200 , 2005, Journal of Lipid Research.

[11]  D. Rozman,et al.  Pre-cholesterol precursors in gametogenesis , 2005, Molecular and Cellular Endocrinology.

[12]  M. Waterman,et al.  Structural Diversities of Active Site in Clinical Azole-bound Forms between Sterol 14α-Demethylases (CYP51s) from Human and Mycobacterium tuberculosis* , 2005, Journal of Biological Chemistry.

[13]  M. Chapman,et al.  Beyond the Statins: New Therapeutic Perspectives in Cardiovascular Disease Prevention , 2005, Cardiovascular drugs and therapy.

[14]  J. Nawarskas.  HMG-CoA reductase inhibitors and coenzyme Q10. , 2005, Cardiology in review.

[15]  Hans-Dieter Höltje,et al.  Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole , 2005, J. Comput. Aided Mol. Des..

[16]  S. Heales,et al.  The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10 , 2005, Drug safety.

[17]  K. Watson,et al.  The past, present, and future of statin therapy. , 2005, Reviews in cardiovascular medicine.

[18]  T. Schulz-Gasch,et al.  Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase , 2004, Nature.

[19]  M. Waterman,et al.  Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology Published, JLR Papers in Press, August 16, 2004. DOI 10.1194/jlr.M400239-JLR200 , 2004, Journal of Lipid Research.

[20]  M. Waterman,et al.  CYP51 from Trypanosoma brucei is obtusifoliol-specific. , 2004, Biochemistry.

[21]  D. Rozman,et al.  A functional cytochrome P450 lanosterol 14 alpha-demethylase CYP51 enzyme in the acrosome: transport through the Golgi and synthesis of meiosis-activating sterols. , 2004, Endocrinology.

[22]  M. Waterman,et al.  Lanosterol metabolism and sterol regulatory element binding protein (SREBP) expression in male germ cell maturation , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  Min Zhang,et al.  Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. , 2003, Journal of medicinal chemistry.

[24]  D. Rozman,et al.  Many facets of mammalian lanosterol 14alpha-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. , 2003, Archives of biochemistry and biophysics.

[25]  M. Waterman,et al.  A cAMP-responsive element binding site is essential for sterol regulation of the human lanosterol 14alpha-demethylase gene (CYP51). , 2002, Molecular endocrinology.

[26]  D. Rozman,et al.  Lanosterol 14α-demethylase and MAS sterols in mammalian gametogenesis , 2002, Molecular and Cellular Endocrinology.

[27]  D. Rozman,et al.  Tissue-specific transcriptional regulation of the cholesterol biosynthetic pathway leads to accumulation of testis meiosis-activating sterol (T-MAS). , 2002, Journal of lipid research.

[28]  M. Waterman,et al.  Folding Requirements Are Different between Sterol 14α-Demethylase (CYP51) from Mycobacterium tuberculosis and Human or Fungal Orthologs* , 2001, The Journal of Biological Chemistry.

[29]  D. Kelly,et al.  An old activity in the cytochrome P450 superfamily (CYP51) and a new story of drugs and resistance. , 2001, Biochemical Society transactions.

[30]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Smith,et al.  A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase. , 2000, Journal of medicinal chemistry.

[32]  M. Waterman,et al.  Cyclic adenosine 3',5'-monophosphate(cAMP)/cAMP-responsive element modulator (CREM)-dependent regulation of cholesterogenic lanosterol 14alpha-demethylase (CYP51) in spermatids. , 1999, Molecular endocrinology.

[33]  D. Kelly,et al.  Characteristics of the heterologously expressed human lanosterol 14α‐demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents , 1999, Yeast.

[34]  M. Waterman,et al.  Elevated Expression of Lanosterol 14α-Demethylase (CYP51) and the Synthesis of Oocyte Meiosis-Activating Sterols in Postmeiotic Germ Cells of Male Rats. , 1998, Endocrinology.

[35]  M. Bock,et al.  Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. , 1997, Journal of medicinal chemistry.

[36]  S. Scherer,et al.  Structure and mapping of the human lanosterol 14alpha-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes. , 1996, Genomics.

[37]  M. Waterman,et al.  The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. , 1996, Archives of biochemistry and biophysics.

[38]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.

[39]  H. Thøgersen,et al.  Chemical structure of sterols that activate oocyte meiosis , 1995, Nature.

[40]  M. Griffioen,et al.  Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. , 1993, Biochemical pharmacology.

[41]  R. Mayer,et al.  Effects of a novel lanosterol 14 alpha-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in Hep G2 cells. , 1991, The Journal of biological chemistry.

[42]  H. Brown,et al.  Selective reductions. 29. A simple technique to achieve an enhanced rate of reduction of representative organic compounds by borane-dimethyl sulfide , 1982 .